Current options in aerosolised drug therapy for children receiving respiratory support

Individualized aerosol medicine: Integrating device into the patient

Pulmonary drug delivery is complex due to several challenges including disease-, patient-, and clinicians-related factors. Although many inhaled medications are available in aerosol medicine, delivering aerosolized medications to patients requires effective disease management. There is a large gap in the knowledge of clinicians who select and provide instructions for the correct use of aerosol devices. Since improper device selection, incorrect inhaler technique, and poor patient adherence to prescribed medications may result in inadequate disease control, individualized aerosol medicine is essential for effective disease management and control. The components of individualized aerosol medicine include: (1) Selecting the right device, (2) Selecting the right interface, (3) Educating the patient effectively, and (4) Increasing patient adherence to therapy. This paper reviews each of these components and provides recommendations to integrate the device and interface into the patient for better clinical outcomes.

Aerosolized drug delivery in awake and anesthetized children to treat bronchospasm

Bronchospasm is a common respiratory adverse event in pediatric anesthesia. First-line treatment commonly includes inhaled salbutamol. This review focuses on the current best practice to deliver aerosolized medications to awake as well as anesthetized pediatric patients and discusses the advantages and disadvantages of various administration techniques. Additionally, we detail the differences between various airway devices used in anesthesia. We highlight the unmet need for innovation of orally inhaled drug products to deliver aerosolized medications during pediatric respiratory critical events such as bronchospasm. It is therefore important that clinicians remain up to date with the best clinical practice for aerosolized drug delivery in order to prevent and efficiently treat pediatric patients experiencing life-threatening respiratory emergencies.

Drug delivery to the pediatric upper airway

Pediatric upper airway disorders are frequently life-threatening and require precise assessment and intervention. Targeting these pathologies remains a challenge for clinicians due to the high complexity of pediatric upper airway anatomy and numerous potential etiologies; the most common treatments include systemic delivery of high dose steroids and antibiotics or complex and invasive surgeries. Furthermore, the majority of innovative airway management technologies are only designed and tested for adults, limiting their widespread implementation in the pediatric population. Here, we provide a comprehensive review of the most recent challenges of managing common pediatric upper airway disorders, describe the limitations of current clinical treatments, and elaborate on how to circumvent those limitations via local controlled drug delivery. Furthermore, we propose future advancements in the field of drug-eluting technologies to improve pediatric upper airway management outcomes.

A path to successful patient outcomes through aerosol drug delivery to children: a narrative review

Although using aerosolized medications is a mainstay of treatment in children with asthma and other respiratory diseases, there are many issues in terms of device and interface selection, delivery technique and dosing, as well as patient and parental education that have not changed for half a century. Also, due to many aerosol devices and interfaces available on the market and the broad range of patient characteristics and requirements, providing effective aerosol therapy to children becomes a challenge. While aerosol delivery devices are equally effective, if they are age-appropriate and used correctly, the majority of aerosol devices require multiple steps to be used efficiently. Unfortunately, many children with pulmonary diseases have problems with the correct delivery technique and do not gain therapeutic benefits from therapy that result in poor disease management and increased healthcare costs. Therefore, the purpose of this paper is to review the current knowledge on aerosol delivery devices used in children and guide clinicians on the optimum device- and interface-selection, delivery technique, and dosing in this patient population. Strategies on how to deliver aerosolized medications in crying and distressed children and how to educate parents on aerosol therapy and promote patient adherence to prescribed medications are also provided. Future directions of aerosol therapy in children should focus on these issues and implement policies and clinical practices that highlight the potential solutions to these problems.

An Innovative Method of Delivering Nebulized Medications for Perioperative Bronchospasm

Perioperative bronchospasm is a common challenge to anesthetic care. The timely delivery of inhaled medications can be challenging, particularly in pediatric patients and in locations where dedicated resources and respiratory support teams are limited. The delivery of nebulized medication to an intubated patient in the operating room can be difficult. We present an innovative method for delivery of nebulized solutions, in which a jet nebulizer is paired with a Mapleson hyperinflation system.

Prescribing patterns and cost-utility analysis of management of childhood asthma in Saudi Arabia: a retrospective cross-sectional study

Objective

This study is based on a retrospective cross-sectional study to assess the prescribing patterns and cost-utility analysis of management of childhood asthma in Saudi Arabia.

Methods

Prescription data were collected for 1 year from electronic records of pharmacy. The unit dose price was retrieved from pharmacy database and compared with daily price based on WHO Defined Daily Dose (DDD) and Saudi Initiative for Asthma (SINA). The cost of each drug is calculated from average prices of each unit dose of each prescription.

Key findings

In male children (57.98%), asthma was more common in comparison to female children (41.02%) at the studied hospital. Salbutamol (44.55%) was the most commonly prescribed medication followed by budesonide (30.97%) and montelukast (12.82%), whereas prednisolone (0.15%) was the least prescribed medication for the management of childhood asthma. It was found that fixed-dose combination of budesonide and formetrol prescribed for the longest duration of therapy (30 days) and imposed highest cost as well [197.10 SR (52.53 USD)] among all the prescribed medicine.

Conclusion

In this study, inhalation route is the most preferred one for management of asthma; this may be due to their fast therapeutic action. Salbutamol was the most popular drug for quick reliever therapy, while budesonide was the most favoured drug for childhood asthma management. Medication prescribed for the management of childhood asthma at the mentioned study centre adhere to SINA guideline.